"If the company was so confident about safe features of its product, it should have come forward and requested us to go for a re-test of the samples or it could have offered other samples for a fresh examination," FDA counsel Darius Khambata submitted before justices V M Kanade and B P Colabawala.
The court was hearing a petition filed by Nestle against FSSAI's June 5 order banning nine variants of Maggi, and Maharashtra government's order prohibiting their sale.
If the company suspected that the FDA reports were not correct then it could have made a grievance before the food regulator to send the samples to an accredited lab in Pune or Nagpur, instead of rushing to the high court to challenge the ban imposed on production and sale of the product, he argued.
Justifying the ban, FDA counsel argued that after tests when FDA found lead content in Maggi to be beyond permissible limit, it issued an order banning the product.
Moreover, FDA had sent lab test reports to Nestle but the company has not included these in the petition, thereby suppressing this fact from the high court, he said.
Both FSSAI and FDA have claimed that they had issued notices to Nestle India keeping in mind the health hazards the product may have had due to the high lead content.
